News Releases

February 23, 2015

RepliCel Submits Clinical Trial Application for its Dermatological Clinical Trial
Autologous cell therapy, RCS-01, to be investigated as a potential treatment for aged, UV-damaged skin VANCOUVER, BC – February 23, 2015 – RepliCel Life... Read full article

January 20, 2015

RepliCel Life Sciences to Present at 11th Annual Phacilitate Cell & Gene Therapy Forum in Washington, DC
VANCOUVER, BC – January 20, 2015 – RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a clinical stage regenerative medicine company focused on the... Read full article

January 7, 2015

RepliCel Life Sciences to Present at Biotech Showcase 2015
Meetings focused on investors, analysts, and potential partners for RCS-01 and RCT-01 cell therapies VANCOUVER, BC – January 7, 2015 – RepliCel Life Sciences... Read full article

December 22, 2014

Newly Released Peer-Reviewed Publication Further Validates RepliCels Use of Dermal Sheath Cup Cells to Treat Pattern Baldness
VANCOUVER, BC – December 22, 2014 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine company focused on the... Read full article

December 2, 2014

RepliCel Life Sciences to Present at World Stem Cell Summit 2014
Over multiple sessions, Lee Buckler will present a RepliCel update, participate in session panels, and lead an experts’ roundtable discussion VANCOUVER, BC – December... Read full article

December 1, 2014

RepliCel Life Sciences Receives Health Canada Clearance for Clinical Trial in Patients with Chronic Achilles Tendinosis
Health Canada Issues “No Objection Letter” for RepliCel’s Phase 1/2 Clinical Trial of RCT-01 VANCOUVER, BC – December 1, 2014 – RepliCel Life Sciences... Read full article

November 26, 2014

RepliCel Announces 2014 Third Quarter Financial Results
VANCOUVER, BC – November 26, 2014 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (TSXV:RP) (OTCQB: REPCF), a clinical stage regenerative medicine company... Read full article

October 29, 2014

RepliCel Submits Clinical Trial Application to Health Canada for its Chronic Achilles Tendinosis Trial
Autologous cell therapy, RCT-01, to be investigated for treatment of tendinopathies refractory to other treatments VANCOUVER, BC – October 29, 2014 – RepliCel Life... Read full article

October 9, 2014

RepliCel to Present Commercial and Clinical Update at BioJapan 2014 World Business Forum
Japanese meetings to focus on partnering VANCOUVER, BC – October 9, 2014 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a clinical stage... Read full article

October 7, 2014

RepliCel Life Sciences Adds Industry Specialist to Management Team
Newly Appointed Vice-President of Business & Corporate Development to Drive External Initiatives VANCOUVER, BC – October 7, 2014 – RepliCel Life Sciences Inc. (OTCQB:... Read full article